Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
opnurasib - KRAS inhibitor
Company overview
Financial review
Conclusions
NCT05132075 KontRASt-02 (CJDQ443B12301)
Non-small cell lung cancer, 2/3L
Indication
Phase
Phase 3
Patients
360
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
Cardiovascular, Renal
and Metabolic
Immunology
Neuroscience
> Oncology
Other
Global Health
Abbreviations
Primary
Outcome
Measures
Arms
Intervention
Target Patients
References
Progression free survival (PFS)
Arm 1 Experimental: JDQ443
Arm 2 Active Comparator: Participant will be treated with docetaxel following local
guidelines as per standard of care and product labels
Patients with advanced non-small cell lung cancer (NSCLC) harboring a KRAS
G12C mutation who have been previously treated with a platinum-based
chemotherapy and immune checkpoint inhibitor therapy either in sequence or in
combination.
Readout
Milestone(s)
2025
Publication
NA
□ NOVARTIS Reimagining Medicine
Novartis Q4 Results | January 31, 2024
73View entire presentation